<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03868592</url>
  </required_header>
  <id_info>
    <org_study_id>17-005349</org_study_id>
    <nct_id>NCT03868592</nct_id>
  </id_info>
  <brief_title>Long-term, Substantial Weight Loss and Insulin Regulation of Lipolysis</brief_title>
  <official_title>Long-term, Substantial Weight Loss and Insulin Regulation of Lipolysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      It is not known how much improvement in insulin regulated lipolysis (the breakdown of
      triglycerides) occurs following substantial, sustained weight loss. Researchers will test the
      effects of inflammation and lipolysis regulation in people before and after bariatric surgery
      (sleeve gastrectomy) to answer these questions.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Study insulin action and adipose function before and after weight loss from gastric sleeve surgery</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Long-term, substantial weight loss and insulin regulation of lipolysis</measure>
    <time_frame>1 year</time_frame>
    <description>Patients will undergo studies of insulin regulation of FFA release combined with adipose biopsies before and one year after bariatric surgery (gastric sleeve). We will relate the improvement in insulin-regulation of lipolysis to changes in adipose tissue inflammation as measured by: 1) changes in the number of pro-inflammatory (CD14+) macrophages; 2) adipose tissue content of IL-6 and TNF</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Long-term, substantial weight loss and insulin regulation of lipolysis</measure>
    <time_frame>1 year</time_frame>
    <description>Patients will undergo studies of insulin regulation of FFA release combined with adipose biopsies before and one year after bariatric surgery (gastric sleeve). We will relate the improvement in insulin-regulation of lipolysis to changes in adipose tissue lipolysis proteins as measured by: 1) changes in adipocyte perilipin 1 and FSP27 relative to HSL and ATGL; 2) changes in adipocyte G0S2 relative to ATGL; 3) changes in adipocyte CGI-58 relative to ATGL; 4) changes in dephosphorylation of adipocyte perilipin 1, ATGL and HSL in response to insulin.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Obesity, Morbid</condition>
  <arm_group>
    <arm_group_label>Gastric sleeve surgery</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>before and after weight loss from bariatric surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Gastric sleeve/bariatric surgery</intervention_name>
    <description>weight loss</description>
    <arm_group_label>Gastric sleeve surgery</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  BMI 40 - 50 kg/m2.

          -  Mo active physical illness that would interfere with mobility or weight loss after
             bariatric surgery

        Exclusion Criteria:

          -  Type 1 or Type 2 Diabetes diagnosis or fasting plasma glucose â‰¥126 mg/dL

          -  Active coronary artery disease

          -  Participation in structured exercise (&gt;2 times per week for 30 minutes or longer)

          -  Smoking

          -  Medications known to affect adipose tissue metabolism (e.g., beta blockers,
             corticosteroids)

          -  Renal insufficiency (serum creatinine &gt; 1.5mg/dl)

          -  Chronic active liver disease (Bilirubin &gt; 17mmol/L, AST &gt; 144 IU/L, or ALT&gt;165IU/L)

          -  Pregnancy or breastfeeding.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael D Jensen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>559055</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>wolhart Sarah, RNSC</last_name>
      <phone>507-255-6940</phone>
      <email>wolhart.sarah@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Michael D Jensen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>March 7, 2019</study_first_submitted>
  <study_first_submitted_qc>March 8, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 11, 2019</study_first_posted>
  <last_update_submitted>July 8, 2020</last_update_submitted>
  <last_update_submitted_qc>July 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Michael D. Jensen</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity, Morbid</mesh_term>
    <mesh_term>Weight Loss</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

